Diabetes News and Research

Latest Diabetes News and Research

Important guidelines from IDF for diabetes care

The Guidelines are the work of the IDF Task Force on Clinical Guidelines, which is focused on meeting the critical global need to provide up-to-date evidence-based information and training for healthcare professionals.

23 Oct 2009

LIVALO statin effective than simvastatin in reducing lipid levels

New Phase III data published today in "Current Medical Research and Opinion" highlight that the recommended starting dose of 2 mg of LIVALO (pitavastatin), a novel synthetic statin, was statistically superior to simvastatin at a dose of 20 mg over 12 weeks in reducing low-density lipoprotein cholesterol

22 Oct 2009

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Bristol-Myers Squibb Company today reported strong sales and earnings growth for the third quarter 2009.

22 Oct 2009

Merck's sales increases by 2% in third quarter 2009

Merck & Co., Inc. today announced financial results for the third quarter of 2009. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the quarter of $0.90, which excludes a $1.7 billion after-tax gain from the sale of the company's interest in Merial Limited as well as restructuring charges and pre-closing merger-related expenses. Third-quarter GAAP EPS was $1.61.

22 Oct 2009

Faster insulin absorption for varying insulin doses and PH20 concentrations demonstrated

Halozyme Therapeutics, Inc. today announced dose response study results that demonstrated faster insulin absorption and increased peak insulin concentrations after co-administration of its recombinant hyaluronidase enzyme (rHuPH20 or PH20) with regular human insulin and with insulin lispro. The enhanced absorption effects were observed at clinically relevant insulin doses across a broad range of PH20 concentrations.

22 Oct 2009

First clinical trial to test a weight maintenance program for obese pregnant women

More than half of women in the United States are overweight or obese when they become pregnant, and most go on to gain more than the recommended amount during pregnancy. The excess weight can lead to a myriad of complications, including preeclampsia, diabetes, bigger babies, C-sections, birth injuries, and weight retention after pregnancy.

22 Oct 2009

Short-listed companies to submit proposals for chronic disease management system

eHealth Ontario and Infrastructure Ontario today announced the three companies short-listed to submit proposals for a chronic disease management system that will be used initially to establish a Diabetes Registry for Ontarians and an eHealth Portal framework.

22 Oct 2009

Obese women retain half of post pregnancy weight

Obese women who gain more than the recommended amount during pregnancy are much more likely to retain a portion of that weight one year after they give birth, according to a Kaiser Permanente study published in the November issue of Obstetrics & Gynecology.

22 Oct 2009

Update from Karo Bio for the period January-September

In an update of the project portfolio, Karo Bio announced, among other things, that the company, in accordance with earlier communicated plans, has submitted an IND application for eprotirome to the American Food and Drug Administration (FDA); that a candidate drug has been nominated within the ER-beta program; and that the company has decided not to initiate further in-house development of KB3305 for the treatment of type 2 diabetes.

22 Oct 2009

Clinical performance study reveals the accuracy and precision of TRUE2go system

Home Diagnostics, Inc., a leading developer, manufacturer, and marketer of blood glucose monitoring systems, today announced the results of a TRUE2go™ clinical performance study published in the October 2009 issue of the journal Diabetes Technology & Therapeutics. The study, “Clinical Performance of the TRUE2go Blood Glucose System – A Novel Integrated System for Meter and Strips,” demonstrated the accuracy and precision of the TRUE2go system and found that it was both easy and convenient to use by patients.

22 Oct 2009

Plant-based foods could help fight obesity and heart disease

The cheeseburger and French fries might look tempting, but eating a serving of broccoli or leafy greens first could help people battle metabolic processes that lead to obesity and heart disease, a new University of Florida study shows.

22 Oct 2009

People in developing countries spend 90% of all medical expenditures for diabetes care

Type 2 diabetes is often seen as a condition affecting older, unproductive adults in wealthy countries. However, the reality is that 70% of people with diabetes now live in low and middle-income countries and the economic impact of diabetes is much greater in poorer countries.

22 Oct 2009

Dose optimization data from Tolerx's Phase 2 clinical study of otelixizumab

Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity, today presented dose optimization data from its Phase 2 clinical study of otelixizumab in subjects with type 1 diabetes. Otelixizumab is a targeted T-cell immunomodulator currently being evaluated in DEFEND, a Phase 3 clinical study in subjects with new-onset autoimmune type 1 diabetes.

22 Oct 2009

VeriChip collaborates with DRI for further development of the glucose-sensing RFID microchip

VeriChip Corporation announced today that it has entered into a strategic partnership with the Diabetes Research Institute ("DRI") to combine efforts on the further development of the glucose-sensing radio frequency identification (RFID) microchip in conjunction with VeriChip's development partner, RECEPTORS LLC.

22 Oct 2009

CHOP implements InforSense-based Translational Research Solution to study complex genetic disease

IDBS, the leading worldwide provider of research data management and analytics solutions to R&D organizations, today announced that The Children's Hospital of Philadelphia (CHOP), one of the leading pediatric hospitals and research facilities in the world, has implemented the InforSense-based Translational Research Solution to advance the understanding of complex genetic disease.

22 Oct 2009

OSI Pharmaceuticals reports total revenues of $111 million for the third quarter of 2009

OSI Pharmaceuticals, Inc. announced today its financial results for the Company’s third quarter ended September 30, 2009. The Company reported total revenues from continuing operations of $111 million for the third quarter of 2009 compared to revenues of $95 million for the third quarter of 2008, an 18% increase over the prior year period.

22 Oct 2009

New findings from ADVANCE clinical trial presented

New analyses of the largest-ever clinical trial of patients with type 2 diabetes show that the combination of blood pressure lowering treatment and intensive glucose (blood sugar) control improved patients' vascular condition and resulted in a significant 18 percent reduction in the risk of death from all causes.

22 Oct 2009

InHealth awards Southern California, Northwestern and Stanford Universities $1.4M as research grants

The Institute for Health Technology Studies (InHealth) has awarded three new research grants totaling more than $1.4 million to investigators at the University of Southern California, Northwestern University, and Stanford University. The funding will support three separate studies that will examine the social and economic impact of therapeutic medical devices, as well as the device innovation process.

22 Oct 2009

Positive results from Isis Pharmaceuticals' ISIS 113715 Phase 2 study in type 2 diabetes patients

Isis Pharmaceuticals, Inc. today announced positive top-line results from a Phase 2 study evaluating the safety and efficacy of ISIS 113715 in patients with type 2 diabetes. ISIS 113715 is a novel insulin sensitizer that reduces the expression of protein tyrosine phosphatase-1B (PTP-1B). The study showed consistent and statistically significant reductions in multiple short and intermediate measures of glucose control.

22 Oct 2009

New partnership to create Translational Orthopedic Research Program

The creation of the Translational Orthopedic Research Program (TORP), a new partnership of Van Andel Research Institute (VARI) and its affiliate the Translational Genomics Research Institute (TGen), Spectrum Health, Orthopaedic Associates of Michigan (OAM), and the Michigan State University (MSU) College of Human Medicine, was announced today by officials of the sponsoring organizations who gathered at Van Andel Institute for the World Osteoporosis Day Summit, a meeting spotlighting local osteoporosis efforts.

22 Oct 2009

Diabetes News and Research

Latest Diabetes News and Research

Important guidelines from IDF for diabetes care

LIVALO statin effective than simvastatin in reducing lipid levels

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Merck's sales increases by 2% in third quarter 2009

Faster insulin absorption for varying insulin doses and PH20 concentrations demonstrated

First clinical trial to test a weight maintenance program for obese pregnant women

Short-listed companies to submit proposals for chronic disease management system

Obese women retain half of post pregnancy weight

Update from Karo Bio for the period January-September

Clinical performance study reveals the accuracy and precision of TRUE2go system

Plant-based foods could help fight obesity and heart disease

People in developing countries spend 90% of all medical expenditures for diabetes care

Dose optimization data from Tolerx's Phase 2 clinical study of otelixizumab

VeriChip collaborates with DRI for further development of the glucose-sensing RFID microchip

CHOP implements InforSense-based Translational Research Solution to study complex genetic disease

OSI Pharmaceuticals reports total revenues of $111 million for the third quarter of 2009

New findings from ADVANCE clinical trial presented

InHealth awards Southern California, Northwestern and Stanford Universities $1.4M as research grants

Positive results from Isis Pharmaceuticals' ISIS 113715 Phase 2 study in type 2 diabetes patients

New partnership to create Translational Orthopedic Research Program

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Diabetes News and Research

Latest Diabetes News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in